Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jul 2021 | FROM AKERO THERAPEUTICS

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Harrison, S. et al. Nature Medicine

Jun 2021 | FROM AKERO THERAPEUTICS

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Frias, J. et al. American Diabetes Association 81st Scientific Sessions

Jun 2021 | FROM AKERO THERAPEUTICS

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Loomba, R . et al. The International Liver Congress ™ 2021 (EASL)

Jun 2021 | FROM AKERO THERAPEUTICS

Increased adiponectin following efruxifermin treatment is associated with improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NAS

Frias, J. et al. American Diabetes Association 81st Scientific Sessions

Jun 2021 | FROM AKERO THERAPEUTICS

Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin

Harrison, S. et al. The International Liver Congress™ 2021 (EASL)

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Tillman, E., and Rolph, T. Frontiers in Endocrinology

Jul 2020 | FROM AKERO THERAPEUTICS

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Kaufman, A. et al. Cell Reports Medicine

Dec 2019 | FROM EXTERNAL EXPERTS

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanya, A. et al. Lancet

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline